0.00Open0.00Pre Close0 Volume0 Open Interest180.00Strike Price0.00Turnover95.54%IV-29.11%PremiumDec 20, 2024Expiry Date73.91Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9900Delta0.0007Gamma3.42Leverage Ratio-0.0703Theta0.0456Rho3.38Eff Leverage0.0108Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet